CJC-1295 + Ipamorelin Safety — Research Reference

*Combined safety profile of the CJC-1295 (with or without DAC) and ipamorelin GH-stimulation stack: water retention, IGF-1 elevation, glucose handling, prolactin/cortisol selectivity, and injection-site signals.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use. Researchers are responsible for compliance with all applicable laws, IRB/IACUC oversight and institutional biosafety policy.

Overview

CJC-1295 (a GHRH analogue, with or without DAC) and ipamorelin (a selective GHRP) are commonly studied together because their complementary mechanisms produce additive GH release without the prolactin and cortisol effects characteristic of older GHRPs.

Reported Adverse Events

• Injection-site reactions: the most frequently reported event in the published Phase 1 data for CJC-1295 (Teichman 2006); transient erythema and pruritus
• Flushing: brief facial flushing, more common with CJC-1295 with DAC due to sustained receptor occupancy
• Headache: mild, transient, dose-related
• Water retention: modest, mechanism-on-target via IGF-1 / GH axis
• Joint or muscle discomfort: dose-related, attributed to GH-induced fluid shifts
• Glucose intolerance: modest fasting glucose elevation and reduced insulin sensitivity at higher CJC-1295 doses, consistent with GH-axis literature
• No significant prolactin or cortisol elevation: ipamorelin's selectivity profile distinguishes it from hexarelin and GHRP-2/6

Phase 1 Reference (CJC-1295)

Teichman et al. (2006) administered single and multiple doses of CJC-1295 with DAC to healthy adults. Dose-related GH and IGF-1 increases were observed for up to 14 days with no significant changes in liver enzymes, cortisol, prolactin, glucose, lipids or hematology beyond the GH-axis itself. Adverse events were predominantly local.

Mechanistic Safety Considerations

• The GHRH + GHRP combination preserves pituitary feedback, theoretically limiting supraphysiologic GH peaks seen with exogenous somatropin
• Long-term carcinogenicity, cardiovascular and metabolic data in humans are absent
• Acromegalic features (soft tissue overgrowth, carpal tunnel) are a theoretical concern at sustained supraphysiologic IGF-1

Practical Research Considerations

Sampling for IGF-1, fasting glucose and HbA1c is standard. Investigators should pre-specify weekly weight, joint symptom scoring and BP/HR monitoring across cycles.

Frequently Asked Research Questions

Does ipamorelin elevate cortisol or prolactin?

Published nonclinical and human pharmacology data show ipamorelin produces GH release without significant cortisol or prolactin elevation, distinguishing it from hexarelin and GHRP-2/6.

Is water retention common with this stack?

Modest, GH-mediated fluid retention is reported, particularly during the first 2–3 weeks of a research cycle. It typically attenuates and is dose-related.

Does CJC-1295 affect glucose?

Modest fasting glucose elevation and a small reduction in insulin sensitivity have been observed at higher doses, consistent with the broader GH-axis literature. Routine fasting glucose and HbA1c sampling is standard.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Frias JP, et al. *Tirzepatide vs semaglutide once weekly.* N Engl J Med. 2021.

1. Jastreboff AM, et al. *Triple–hormone-receptor agonist retatrutide for obesity.* N Engl J Med. 2023.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC 157 — review.* Curr Pharm Des. 2018.

1. Goldman MP. *Photoprotection and α-MSH analogues.* J Drugs Dermatol. 2010.

1. Teichman SL, et al. *Prolonged stimulation of GH and IGF-1 secretion by CJC-1295.* J Clin Endocrinol Metab. 2006.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Pickart L, Margolina A. *Regenerative and protective actions of the GHK-Cu peptide.* Int J Mol Sci. 2018.